Finerenone in pediatric chronic kidney disease with proteinuria on ACE inhibitor or ARB therapy

Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Finerenone plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Mean reduction in urinary protein-to-creatinine ratio at Month 6. Started May 2022; status: completed.